Tech Company Financing Transactions
Cognition Therapeutics Funding Round
Golden Seeds, Ariel Southeast Angel Partners and Cowtown Angel Network invested in a $12 million Series B funding round for Cognition Therapeutics. This venture round closed on 7/22/2015.
Transaction Overview
Company Name
Announced On
7/22/2015
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$12,000,000
Round
Series B
Investors
Proceeds Purpose
CogRx will focus on advancing its first-in-class lead Alzheimer's program into Phase 1 clinical studies by the end of 2015. The Company's small molecule Abeta oligomer displacement drug has the potential to rapidly improve and possibly reverse the symptoms of Alzheimer's disease and to stop disease progression. In addition, the Company is using the funds to advance next generation compounds and unlock the potential of its platform for discovering drugs for other protein misfolding nervous system diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2403 Sidney St. 261
Pittsburgh, PA 15203
USA
Pittsburgh, PA 15203
USA
Phone
Website
Email Address
Overview
Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimers disease and other neurodegenerative disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kenneth Moch
Chief Financial Officer
Stephen DiPalma
Chief Medical Officer
Gilbert Rishton
Chief Scientific Officer
Susan Catalano
Browse more venture capital transactions:
Prev: 7/22/2015: Viyet venture capital transaction
Next: 7/22/2015: DataFox venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs